Applied Therapeutics — Investor Presentation (February 2022)
38 slides from Applied Therapeutics's investor presentation, Feb 15, 2022
Slide 1: This presentation is made by Applied Therapeutics, Inc.(the “Company”). Nothing contained in this presentation
This presentation is made by Applied Therapeutics, Inc.(the “Company”). Nothing contained in this presentation is, or should be construed as, a recommendation, promise or representation by the presenter or the Company or any director, employee, agent, or adviser of the Company. This presentation doe
Slide 2: Applying Science to Transform Lives
3 Applying Science to Transform Lives Our mission is to create transformative, life-changing treatments for patients who desperately need them Targeting pathways with known roles in pathogenesis Novel compounds with improved potency/selectivity SCIENCE Clinical efficacy confirmed via biomarkers Purs
Slide 3: Innovative Pipeline with Near-Term Milestones
AT-104 Compound Preclinical Phase 1 Phase 2 Phase 3 AT-007 AT-007 AT-007 AT-001 AT-001 AT-003 4 Innovative Pipeline with Near-Term Milestones SORD Deficiency PMM2-CDG Diabetic Cardiomyopathy Diabetic Peripheral Neuropathy Diabetic Retinopathy Galactosemia QD Oral CNS Positive adult and pediatric bio
Slide 4: Aldose Reductase Inhibitor Overview
ALDOSE REDUCTASE Aldose Reductase is an enzyme implicated in multiple metabolic diseases First and rate limiting enzyme in the polyol pathway – an alternative metabolic pathway activated under stress Converts sugar to reduced sugar alcohols, which are toxic Prior attempts to inhibit Aldose Reductase
Slide 5: AT-007: Blockbuster Opportunity with Late-Stage Programs in 2 Rare Diseases
AT-007: Blockbuster Opportunity with Late-Stage Programs in 2 Rare Diseases with High Unmet Need and No Approved Treatments 6 • Positive adult and pediatric biomarker data • Orphan Drug Designation • Pediatric Rare Disease Designation • Fast-Track Designation • Phase 3 pediatric outcomes study ongoi
Slide 6: AT-001: Potential First Therapy in Diabetic Cardiomyopathy
7 AT-001: Potential First Therapy in Diabetic Cardiomyopathy, a Highly Prevalent Disease with Blockbuster Potential • Heart Failure affecting ~20% of diabetics • Positive proof of concept in Phase 1/2 • ARISE-HF global Phase 3 trial ongoing; data expected 2023 • No drugs approved; potential first di
Slide 7: AT-007 Galactosemia
AT-007 GALACTOSEMIA Positive adult & pediatric biomarker data Pediatric Ph 3 clinical outcomes study ongoing • Orphan Drug Designation • Pediatric Rare Disease Designation (PRV) • Fast-Track Designation
Slide 8: Galactosemia is a Rare Metabolic Disease With No Approved Therapies
Galactosemia is a Rare Metabolic Disease With No Approved Therapies and Significant Unmet Need Disease Overview • Rare autosomal recessive metabolic disease caused by deficiencies in the GALT or GALK enzymes • Patients are unable to metabolize the simple sugar galactose, which is found in foods but
Slide 9: AT-007 Has Demonstrated Effectiveness In Vitro, In Vivo, and in Phase 1/2 Trials
10 In Vitro Pediatric Phase 1-2 Pediatric Phase 3 • Aldose Reductase inhibition: 1,000X greater potency • Selectivity: no off-target aldehyde reductase inhibition Animal Model • Prevents CNS complications (learning/ cognition) and cataracts in a rat model of Classic Galactosemia • Decreases toxic ga
Slide 10: Deficiency in GALT or GALK Leads to Inability to Metabolize Galactose
Deficiency in GALT or GALK Leads to Inability to Metabolize Galactose; AR Converts Excess Galactose to Toxic Galactitol Energy Production GALK GALT NORMAL METABOLISM Classic Galactosemia GALK Deficiency ALDOSE REDUCTASE galactitol toxic accumulation of galactitol galactitol no natural enzyme to meta
Slide 11: Natural History: Galactosemia is a Progressive Disease
12 Natural History: Galactosemia is a Progressive Disease that Worsens with Age; Disease Severity Correlates with Plasma Galactitol Level Speech Cognition Behavior Motor Skills Abstract eP011: Progressive Worsening of Central Nervous System Phenotype in Children with Classic Galactosemia: a Cross-Se
Slide 12: AT-007 Reduced Toxic Galactitol Levels in a Rat Model of Galactosemia
In a Rat Model of Galactosemia, AT-007 Significantly Reduced Toxic Galactitol Levels in All Target Tissues and Normalized the CNS Phenotype Wild Type GALT null placebo GALT null AT-007 0 4 8 12 16 20 Liver Brain Plasma Galactitol (Toxic Metabolite) pmol PRE-CLINICAL 0 10 20 30 40 1 2 3 4 Time (sec)
Slide 13: AT-007 Significantly Reduced Galactitol in Adult Phase 1/2 Study
AT-007 Significantly Reduced Galactitol Levels in the Galactosemia Adult Phase 1/2 Study (ACTION-Galactosemia); Safe and Well-Tolerated Single Ascending Dose (n=40) Multiple Ascending Dose (n=40, 7 days) 5 mg/kg single dose 5 mg/kg 27 Days Daily Dosing (n=4) Adult Galactosemia Patients Healthy Volun
Slide 14: AT-007 Reduced Galactitol in ACTION-Galactosemia Kids Pediatric Study
0.01 (20 mg/kg and 40 mg/kg vs. placebo) 15 AT-007 Significantly Reduced Galactitol Levels in the ACTION- Galactosemia Kids Pediatric Registrational Clinical Study AT-007 Dose Escalation Biomarker Assessment of Galactitol Placebo cross to active once treatment effect on outcomes is demonstrated PK/P
Slide 15: Commercial Preparations On-Track for U.S. Galactosemia Launch
No compensatory increase in galactose or Gal-1p Commercial Preparations On-Track for U.S. Galactosemia Launch 16 U.S. Map of Galactosemia KOL Medical Genetics Centers of Excellence (COEs)* Commercialization Preparations Support an Optimized Launch at Approval • Sales force segmentation, targeting an
Slide 16: Award Winning DSA Campaign Performance Reflects Strong Demand
Award Winning DSA Campaign Performance Reflects Underlying Strong Demand for Galactosemia Education and Treatment 17 Awards Engaging the Galactosemia Community through Social 35,000+ post views 537 Facebook followers Support and Education at Galactosemia.com 100,000+ website visitors Sharing the Gal
Slide 17: AT-007 SORD Deficiency
AT-007 SORD DEFICIENCY Preclinical proof of concept demonstrated Positive pilot study completed Registrational Phase 2/3 study ongoing •
Slide 18: SORD Deficiency is a Rare Neurological Disease with No Approved Therapies
Orphan Drug Designation SORD Deficiency is a Rare Neurological Disease with No Approved Therapies and High Unmet Need Disease Overview • Sorbitol Dehydrogenase Deficiency (SORD Deficiency) is a progressive, debilitating hereditary neuropathy that affects peripheral nerves and motor neurons, resultin
Slide 19: AT-007 Has Demonstrated Effectiveness In Vitro, In Vivo, and in a SORD Pilot Study
Aldose Reductase Inhibitor 20 In Vitro Pilot Study Phase 3 • Aldose Reductase inhibition: 1,000X greater potency • Selectivity: no off-target aldehyde reductase inhibition Animal Model • Prevents oxidative stress, neuronal degeneration and mobility phenotype in drosophila SORD model • Safe and well
Slide 20: Aldose Reductase Inhibition Addresses the Underlying Cause of SORD Neuropathy
Reduces sorbitol levels in cultured fibroblasts and motor neurons from SORD Deficiency patients 21 Aldose Reductase Inhibition Addresses the Underlying Cause of SORD Neuropathy by Preventing Conversion of Glucose to Sorbitol sorbitol Hexokinase Pathway ALDOSE REDUCTASE Energy polyol pathway AT-007 •
Slide 21: AT-007 Reduces Sorbitol Levels in SORD Patient Cells
22 AT-007 Treatment Reduces Sorbitol Levels in SORD Patient Cells; Prevents CNS Phenotype in a Drosophila SORD Deficiency Model • Cultured fibroblasts from SORD patients accumulate sorbitol levels up to 100X higher than healthy controls • Treatment with AT-007 in culture significantly reduced sorbit
Slide 22: AT-007 Significantly Reduced Sorbitol in 30-Day Open-Label Pilot Trial
AT-007 Significantly Reduced Sorbitol in Patients with SORD Deficiency in 30-Day Open-Label Pilot Trial 23 Mean baseline sorbitol level was ~38,000ng/ml; individual % reduction from baseline noted above green bar Pilot open-label study data in 8 SORD patients demonstrated 66% mean reduction in sorbi
Slide 23: SORD Neuropathy Phase 2/3 Registrational Study (INSPIRE)
SORD Neuropathy Phase 2/3 Registrational Study (INSPIRE) Double-Blind, Randomized, Placebo-Controlled Multi-Center Study in ~50 SORD Patients >16 years old Primary Biomarker Efficacy: Reduction in sorbitol vs. baseline at 3 months Additional Biomarker: NFL reduction at 3 months CMT-FOM lower limb do
Slide 24: Inherited Neuropathy Consortium Centers of Excellence Support Trial Enrollment
25 Inherited Neuropathy Consortium Centers of Excellence and Global CMT Registries Exist to Support Trial Enrollment & Treatment Cedars-Sinai Medical Center, LA Stanford University, Palo Alto University of Colorado Massachusetts General Hospital, Boston Connecticut Children’s Medical Center Universi
Slide 25: AT-007 Granted Orphan & Pediatric Rare Disease Designation for PMM2-CDG
26 Aldose Reductase Inhibition Improves PMM2 Activity AT-007 Granted Orphan & Pediatric Rare Disease Designation for PMM2-CDG; Single-Patient IND Open – Phase 2 Ready sorbitol glucose Normal Metabolism ALDOSE REDUCTASE Protein Glycosylation polyol pathway activation AT-007 • AR inhibition blocks the
Slide 26: AT-001 Diabetic Cardiomyopathy
AT-001 DIABETIC CARDIOMYOPATHY Phase 1/2 pilot study completed Registrational Phase 3 study ongoing
Slide 27: Diabetic Cardiomyopathy is a Form of Heart Failure Affecting ~20% of Diabetics
Diabetic Cardiomyopathy is a Form of Heart Failure Affecting ~20% of Diabetics; Significant Unmet Need with No Approved Treatments Disease Overview • Form of Heart Failure (Stage B) causing structural cardiac damage and resulting in decreased cardiac functional capacity • Affects ~20% of diabetics •
Slide 28: DbCM: Mechanism of Disease
Aldose Reductase, the first and rate limiting enzyme in the polyol pathway, converts this glucose into sorbitol and eventually fructose Both Type 1 and Type 2 diabetes results in hyperglycemia; the polyol pathway is then hyperactivated to rid the body of the excess glucose Excess sorbitol and fructo
Slide 29: Diabetic Cardiomyopathy is a Form of Stage B Heart Failure
30 • Cardiac structural abnormalities (LVH, GLS, LAE, E/e’) • Early symptoms of DbCM; noticeable impact on activities • Impaired functional capacity (~75% normal) • Overt Heart Failure • HFpEF or HFrEF • Significant impact on daily activities • Refractory Heart Failure requiring specialized interven
Slide 30: AT-001 Has Demonstrated Effectiveness In Vitro, In Vivo, and in Phase 1/2 Trials
31 In Vitro Cell Culture Phase 1/2 Phase 3 Study • Aldose Reductase inhibition: 1,000X greater potency • Selectivity: no off-target aldehyde reductase inhibition Prevents ROS formation, mitochondrial dysfunction and senescence in cells in culture Animal Model Improves cardiac energetics and prevents
Slide 31: AT-001 Provides Greater Potency and Selectivity vs. Old Aldose Reductase Inhibitors
32 Poster # 632: “Addressing safety and specificity with aldose reductase inhibition: development of AT-001 for diabetic cardiomyopathy” 56th Annual Meeting of the European Association for the Study of Diabetes (EASD) Sept 2020 In Vitro: AT-001 Provides Greater Potency and Improved Target Selectivit
Slide 32: AT-001 Treatment Prevents Reactive Oxygen Species Formation
Dihydroethidium(DHE) staining for cytosolic reactive oxygen species HG HG + AT001 D H E HG-NHK cells exposed to 25mM glucose for 48hrs HG + AT001 - cells treated with 0.18nM AT001 along with above mentioned HG exposure Cytosolic reactive oxygen species attenuated by AT 001 in skin cells treated with
Slide 33: AT-001 Prevents Abnormal Cardiac Energy Metabolism in Animal Model of DbCM
34 METHODS & EXPERIMENTAL DESIGN 60% High-Fat Diet Week Mouse euthanized & heart extracted for isolated working heart perfusion Echo Echo AT-001 (20 mg/kg daily) C57BL/6J hAR-Tg 8 weeks old Streptozotocin (75 mg/kg) To assess left-ventricular function and wall dimensions hAR-Tg: human Aldose Reducta
Slide 34: Phase 1: AT-001 Normalizes Sorbitol in Diabetic Patients
35 Poster, “Phase 1/2 Safety and Proof of Biological Activity Study of AT-001, an Aldose Reductase Inhibitor in Development for Diabetic Cardiomyopathy” American Diabetes Association 79th Scientific Sessions in San Francisco (June 7-11, 2019); Poster “Clinical Assessment of AT-001, an Aldose Reducta
Slide 35: Phase 2: AT-001 Reduced Levels of NTproBNP Cardiac Stress Biomarker
Phase 2: AT-001 Reduced Levels of NTproBNP Cardiac Stress Biomarker Over 28 Days -50 -40 -30 -20 -10 0 10 % change from baseline to Cmax -25 -20 -15 -10 -5 0 Mean reduction in NTproBNP 0 - 28 days 0 10 20 30 40 50 60 placebo 1000mg TID 1500mg BID Placebo (n=6) 1,000mg TID (n=12) 1,500mg BID (n=12) %
Slide 36: DbCM Phase 3 Registrational Study (ARISE-HF)
DbCM Phase 3 Registrational Study (ARISE-HF) Randomized, Placebo-Controlled Study in DbCM Patients at High Risk of Progression Core Study Efficacy (15 Months) • Primary Endpoint: Functional Capacity (as measured by Peak VO2 change from baseline) Study Population Patients with DbCM at high risk of pr
Slide 37: Key Projected Milestones by Program
Full Enrollment (Midyear 2022) 15 Month Clinical Outcomes Primary Endpoint Peak VO2 27 Month Clinical Outcomes including morbidity/ mortality DbCM DbCM Phase 3 Key Projected Milestones by Program 38 2022 2023 2024 Full Enrollment Target 3- Month Biomarker Data – Sorbitol & NFL 12 Month Data: Muscle
Slide 38: Key Projected Milestones by Program
Key Projected Milestones by Program o = 6 Month 12 Month 18 Month Gg Clinical Outcomes Clinical Outcomes Clinical Outcomes je} xs) & Galactosemia Pediatric Phase 3 Open Label oO 0) a Full Enrollment 3- Month Biomarker 12 Month Data: Muscle MRI & 24 Month Data x Target Data — Sorbitol & NFL Clinical
Applied Therapeutics — Investor Presentation (February 2022) on 6ix